|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
|
DISC MEDICINE, INC. (Name of Issuer) |
Common Stock, $0.0001 par value per share (Title of Class of Securities) |
254604101 (CUSIP Number) |
Ommer Chohan, CFO Atlas Venture, 300 Technology Square, 8th Floor Cambridge, MA, 02139 (857) 201-2700 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
12/12/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Fund X, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
813,167.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
2.2 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
ATLAS VENTURE ASSOCIATES X, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
813,167.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
2.2 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Associates X, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
813,167.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
2.2 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Fund XII, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
14,013.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Associates XII, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
14,013.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Associates XII, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
14,013.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Opportunity Fund I, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
349,210.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Associates Opportunity I, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
349,210.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Associates Opportunity I, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
349,210.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Opportunity Fund II, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
337,485.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Associates Opportunity II, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
337,485.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 254604101 |
| 1 |
Name of reporting person
Atlas Venture Associates Opportunity II, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
337,485.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, $0.0001 par value per share | |
| (b) | Name of Issuer:
DISC MEDICINE, INC. | |
| (c) | Address of Issuer's Principal Executive Offices:
321 ARSENAL STREET, SUITE 101, WATERTOWN,
MASSACHUSETTS
, 02472. | |
Item 1 Comment:
This Amendment No. 5 to Schedule 13D ("Amendment No. 5") is being filed as an amendment to the statement on Schedule 13D relating to common stock, par value $0.0001 per share of Disc Medicine, Inc., a Delaware corporation, as filed with the Securities and Exchange Commission (the "SEC") on February 16, 2021 (the "Initial Schedule 13D") and later amended on February 14, 2023 ("Amendment No. 1") , September 21, 2023 ("Amendment No. 2"), January 24, 2024 ("Amendment No. 3"), and August 15, 2025 ("Amendment No. 4") and together with the Initial Schedule 13D, Amendment No. 1, Amendment No. 2 and Amendment No. 3, the "Prior Schedule 13D"). All capitalized terms not otherwise defined herein shall have the meanings ascribed to the terms in the Prior Schedule 13D. The Prior Schedule 13D is hereby amended and supplemented as follows and, except as expressly amended below, the Prior Schedule 13D remains in full force and effect. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | As of the date hereof, Atlas X is the record owner of 813,167 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X.
As of the date hereof, Atlas XII is the record owner of 14,013 shares of Common Stock. AVA XII LP is the general partner of Atlas XII and AVA XII LLC is the general partner of AVA XII LP. Each of Atlas XII, AVA XII LP and AVA XII LLC has shared voting and dispositive power over the shares held by Atlas XII. As such, each of Atlas XII, AVA XII LP and AVA XII LLC may be deemed to beneficially own the shares held by Atlas XII.
As of the date hereof, AVOF is the record owner of 349,210 shares of Common Stock. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVOF, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVOF. As such, each of AVOF, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVOF.
As of the date hereof, AVOF II is the record owner of 337,485 shares of Common Stock. AVAO II LP is the general partner of AVOF II and AVAO II LLC is the general partner of AVAO II LP. Each of AVOF II, AVAO II LP and AVAO II LLC has shared voting and dispositive power over the shares held by AVOF II. As such, each of AVOF II, AVAO II LP and AVAO II LLC may be deemed to beneficially own the shares held by AVOF II.
Each of the Fund X Reporting Persons, Fund XII Reporting Persons, Opportunity Fund Reporting Persons and Opportunity Fund II Reporting Persons may be deemed to beneficially own 2.2%, 0.0%, 0.9% and 0.9%, respectively, of the Issuer's outstanding Common Stock, which percentages are calculated based upon 37,750,162 shares of Common Stock outstanding as of October 31, 2025, as reported in the Issuer's Quarterly Report for the quarterly period ended September 30, 2025 on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2025.
Collectively, the Reporting Persons beneficially own an aggregate of 1,513,875 shares of Common Stock, which represents an estimated 4.0% of the Issuer's outstanding Common Stock. The Fund X Reporting Persons, Fund XII Reporting Persons, Opportunity Fund Reporting Persons and the Opportunity Fund II Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes. | |
| (b) | As of the date hereof, each of Atlas X, AVA X LP and AVA X LLC have shared voting power and shared dispositive power over 813,167 shares of Common Stock.
As of the date hereof, each of Atlas XII, AVA XII LP and AVA XII LLC have shared voting power and shared dispositive power over 14,013 shares of Common Stock.
As of the date hereof, each of AVOF, AVAO LP and AVAO LLC have shared voting power and shared dispositive power over 349,210 shares of Common Stock.
As of the date hereof, each of AVOF II, AVAO II LP and AVAO II LLC have shared voting power and shared dispositive power over 337,485 shares of Common Stock. | |
| (c) | The transactions in the common stock by the Reporting Persons during the past sixty days are set forth in Exhibit 99.1 and are incorporated herein by reference. | |
| (e) | The Reporting Persons ceased to be the beneficial owners of more than five percent of the common stock on or before October 31, 2025 by virtue of dilution resulting from the Issuer's issuance of additional shares of common stock and not as a result of any transaction by the Reporting Persons. | |
| Item 7. | Material to be Filed as Exhibits. | |
Transactions in Common Stock During the Past Sixty Days | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit 99.1
JOINT FILING AGREEMENT
Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned.
Date: December 17, 2025
| Atlas Venture Fund X, L.P. | |
|
|
|
| By: | Atlas Venture Associates X, L.P., its general partner |
| By: | Atlas Venture Associates X, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| ||
| Atlas Venture Associates X, L.P. | |
|
|
|
| By: | Atlas Venture Associates X, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| ||
| Atlas Venture Associates X, LLC | |
|
|
|
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| Atlas Venture Opportunity Fund I, L.P. | |
|
|
|
| By: | Atlas Venture Associates Opportunity I, L.P., its general partner |
| By: | Atlas Venture Associates Opportunity I, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| ||
| Atlas Venture Associates Opportunity I, L.P. | |
|
|
|
| By: | Atlas Venture Associates Opportunity I, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| Atlas Venture Associates Opportunity I, LLC | |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
|
|
|
| Atlas Venture Fund XII, L.P. | |
|
|
|
| By: | Atlas Venture Associates XII, L.P., its general partner |
| By: | Atlas Venture Associates XII, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| ||
| Atlas Venture Associates XII, L.P. | |
|
|
|
| By: | Atlas Venture Associates XII, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| ||
| Atlas Venture Associates XII, LLC | |
|
|
|
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| Atlas Venture Opportunity Fund II, L.P. | |
|
|
|
| By: | Atlas Venture Associates Opportunity II, L.P., its general partner |
| By: | Atlas Venture Associates Opportunity II, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| ||
| Atlas Venture Associates Opportunity II, L.P. | |
|
|
|
| By: | Atlas Venture Associates Opportunity II, LLC, its general partner |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
| Atlas Venture Associates Opportunity II, LLC | |
| ||
| By: /s/ Ommer Chohan | |
| Name: | Ommer Chohan |
| Title: | Chief Financial Officer |
Transactions in Common Stock During the Past Sixty Days
Reporting Person | Nature of the Transaction | Amount of Securities Sold | Weighted Average Price ($) | Date of Sale | Low Price ($) | High Price ($) |
Atlas X | Sale of Common Stock | 34,136 | 92.05 | 12/12/2025 | 91.5289 | 92.4325 |
AVOF | Sale of Common Stock | 16,403 | 92.05 | 12/12/2025 | 91.5289 | 92.4325 |
AVOF II | Sale of Common Stock | 8,527 | 92.05 | 12/12/2025 | 91.5289 | 92.4325 |
Atlas XII | Sale of Common Stock | 6,570 | 92.05 | 12/12/2025 | 91.5289 | 92.4325 |
Atlas X | Sale of Common Stock | 8,012 | 92.58 | 12/12/2025 | 92.52 | 93.3796 |
AVOF | Sale of Common Stock | 3,852 | 92.58 | 12/12/2025 | 92.52 | 93.3796 |
AVOF II | Sale of Common Stock | 2,005 | 92.58 | 12/12/2025 | 92.52 | 93.3796 |
Atlas XII | Sale of Common Stock | 1,540 | 92.58 | 12/12/2025 | 92.52 | 93.3796 |
Atlas X | Sale of Common Stock | 7,151 | 93.80 | 12/12/2025 | 93.52 | 94.255 |
AVOF | Sale of Common Stock | 3,446 | 93.80 | 12/12/2025 | 93.52 | 94.255 |
AVOF II | Sale of Common Stock | 1,793 | 93.80 | 12/12/2025 | 93.52 | 94.255 |
Atlas XII | Sale of Common Stock | 1,371 | 93.80 | 12/12/2025 | 93.52 | 94.255 |
Atlas X | Sale of Common Stock | 60,725 | 91.18 | 12/15/2025 | 91.00 | 91.99 |
AVOF | Sale of Common Stock | 28,913 | 91.18 | 12/15/2025 | 91.00 | 91.99 |
AVOF II | Sale of Common Stock | 14,811 | 91.18 | 12/15/2025 | 91.00 | 91.99 |
Atlas XII | Sale of Common Stock | 11,427 | 91.18 | 12/15/2025 | 91.00 | 91.99 |
Atlas X | Sale of Common Stock | 8,187 | 92.01 | 12/15/2025 | 92.00 | 91.48 |
AVOF | Sale of Common Stock | 3,921 | 92.01 | 12/15/2025 | 92.00 | 91.48 |
AVOF II | Sale of Common Stock | 2,049 | 92.01 | 12/15/2025 | 92.00 | 91.48 |
Atlas XII | Sale of Common Stock | 1,572 | 92.01 | 12/15/2025 | 92.00 | 91.48 |
Atlas X | Sale of Common Stock | 74,666 | 91.24 | 12/16/2025 | 91.00 | 91.705 |
AVOF | Sale of Common Stock | 35,898 | 91.24 | 12/16/2025 | 91.00 | 91.705 |
AVOF II | Sale of Common Stock | 18,666 | 91.24 | 12/16/2025 | 91.00 | 91.705 |
Atlas XII | Sale of Common Stock | 14,359 | 91.24 | 12/16/2025 | 91.00 | 91.705 |
Atlas X | Sale of Common Stock | 818 | 91.47 | 12/17/2025 | 91.2501 | 91.52 |
AVOF | Sale of Common Stock | 393 | 91.47 | 12/17/2025 | 91.2501 | 91.52 |
AVOF II | Sale of Common Stock | 213 | 91.47 | 12/17/2025 | 91.2501 | 91.52 |
Atlas XII | Sale of Common Stock | 148 | 91.47 | 12/17/2025 | 91.2501 | 91.52 |